Vice President MDx Development, Head of Sample Technologies
PreAnalytiX Management Committee Co-Chair
Dr. Oelmueller joined QIAGEN in 1995. He is Vice President, Head of the Molecular Diagnostics Department for Sample Technologies. At the QIAGEN / BD joint venture company PreAnalytiX he is QIAGEN’s Management Committee Co-Chair. Dr. Oelmueller was the coordinator of the EU FP7 Collaborative Grant Project SPIDIA (2008 – 2013) and is the current coordinator of the EU Horizon 2020 Coordination and Support Action SPDIA4P (2017 – 2020). Both projects focus on the standardization and improvement of pre-analytical workflows for in-vitro diagnostics. He is a working group convener at the ISO/TC 212 (clinical Laboratory testing and in vitro diagnostic test systems) and at the CEN/TC 140 (in vitro diagnostic medical devices). In 2017 he received in Stockholm the “DIN Honorary Needle” Award for his international engagement in standards developments for quality management in medical laboratories and in 2020 in Brussels the CEN-CENELEC “Standard and Innovation Technical Body Officers Award” for successfully introducing research outcome and innovation into standardization.
The SPIDIA project received funding from under the 7th Research Framework Programme of the European Union, under grant agreement no. 222916. SPIDIA4P project receives funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement no. 733112.